B-Clear Study

STUDY BASICS

Do you have chronic hepatitis B? Are you age 18 or older? You may be able to participate in a research study to help find out if an experimental new drug is safe and effective for the treatment of chronic hepatitis B. Participation involves multiple visits over 55 weeks. Compensation is provided.

STUDY PURPOSE

Hepatitis B is a virus that infects the liver. Although most adults who become infected with hepatitis B recover quickly, babies and children infected with hepatitis B may be more likely to develop chronic (long term) infection. Over time, people with chronic hepatitis B can develop serious liver disease and symptoms such as fatigue, pain, nausea and vomiting, and yellowing of the eyes and skin. Medications can help people manage hepatitis B but there is currently no cure for the disease.  

The purpose of this research study is to find out if an experimental new drug called GSK3228836 is safe and effective for the treatment of chronic hepatitis B. The study drug GSK3228836 is designed to work with the body’s immune system to help gain control over the virus. GSK3228836 is not approved by the United States Food and Drug Administration (FDA) for use in people living with chronic hepatitis B.  

COULD THIS STUDY BE RIGHT FOR YOU?

• Diagnosed with chronic hepatitis B
• Not diagnosed with HIV, hepatitis C, hepatitis D, uncontrolled diabetes, liver cirrhosis, liver cancer, systemic lupus erythematosus, and/or rheumatoid arthritis
• Not pregnant or breastfeeding

WHAT PARTICIPANTS CAN EXPECT

Study participation involves multiple visits over 55 weeks. All participants will receive the study drug GSK3228836 at some point during the study. Some participants may also receive a placebo (does not contain study drug) at some point during the study. Both the study drug and the placebo are given by injection. Tests and assessments during the study include physical exams, blood draws, and urine collections.  After the study treatment period, participants will continue to be monitored for an additional 24 weeks.